A study to evaluate an oral medication, Siponimod (BAF312), in patients with Secondary Progressive Multiple Sclerosis

Recruiting
18 years - 60 years
All
Phase
3
1 Location
Brief description of study
The main purpose of the study is to see how effective and safe BAF312 is compared to a Placebo in patients with Secondary Progressive MS. A placebo is a “pill” (capsule or tablet) with no medicine inside. A placebo is used to make sure that the changes you report are just not happening by chance, ex. by comparing the results in patients taking BAF312 to those in patients taking placebo. By participating in this trial, you will either receive BAF312 or a Placebo.
Detailed description of study
This study includes 3 parts: 1. A screening phase- to see if you are eligible to participate in this study, 2. A study drug/placebo treatment phase- this will include visits (which will occur every three months after the Day 1, Day 7 and Day 28 visits) that will monitor you throughout the study while taking the study drug or placebo, and 3. A follow-up phase, which will include safety assessments, but will not involve the administration of study drug or placebo.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Multiple sclerosis,Secondary Progressive
-
Age: 18 years - 60 years
-
Gender: All
Updated on
19 Feb 2024.
Study ID: 819215